Orange Book product · Brand (NDA)
INBRIJA
LEVODOPA
At a glance
Dec 21, 2018
Approved
Brand (NDA)
Application
Not listed
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 21, 2018
7 yr 7 mo ago
Today
Patent RE43711 expires
Listed method-of-use patent (U-2484) expiration.
Feb 03, 2029
in 2 yr 8 mo
Patent 8545878 expires
Listed drug product patent expiration.
Nov 16, 2032
in 6 yr 6 mo
Patent 8685442 expires
Listed drug product patent expiration.
Nov 16, 2032
in 6 yr 6 mo
Patent 8945612 expires
Listed drug product patent expiration.
Nov 16, 2032
in 6 yr 6 mo
Patent 9393210 expires
Listed drug product patent expiration.
Nov 16, 2032
in 6 yr 6 mo
Patent 12458615 expires
Listed method-of-use patent (U-2484) expiration.
Oct 21, 2033
in 7 yr 5 mo
Pharmaceutical detail
Active ingredient
LEVODOPA
Strength
42MG
Dosage form
POWDER
Route
INHALATION
TE code
Not listed
Application
NDA 209184
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| RE43711 | Feb 03, 2029 | in 2 yr 8 mo | U-2484 |
| 8545878 | Nov 16, 2032 | in 6 yr 6 mo | Product |
| 8685442 | Nov 16, 2032 | in 6 yr 6 mo | Product |
| 8945612 | Nov 16, 2032 | in 6 yr 6 mo | Product |
| 9393210 | Nov 16, 2032 | in 6 yr 6 mo | Product |
| 12458615 | Oct 21, 2033 | in 7 yr 5 mo | U-2484 |
